{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:18:12Z","timestamp":1783333092369,"version":"3.54.6"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to describe the population pharmacokinetic (PK) of meropenem in patients with mixed Gram\u2010negative bacterial infections, and further to develop optimal dosing regimens for both non\u2010critically ill and critically ill patients by combining different pharmacokinetic\/pharmacodynamic (PK\/PD) targets. Based on retrospectively collected data from patients who underwent therapeutic drug monitoring (TDM) for meropenem, including demographic characteristics, medication records, and laboratory results, a population PK model was developed via nonlinear mixed\u2010effects modeling. Dosing regimens were subsequently evaluated and provided through Monte Carlo simulation. The population PK analysis of meropenem included 86 steady\u2010state concentrations from 39 adult patients. The data were modeled using a one\u2010compartment model. The final model yielded a population typical value for clearance (CL) of 6.10 L\/h. Our study showed that estimated glomerular filtration rate (eGFR) significantly affected the PK of meropenem. Monte Carlo simulation results demonstrated that a regimen of 0.5\u2010h infusion every 8 h was sufficient to achieve the conventional target of 40%\n                    <jats:italic>\u0192<\/jats:italic>\n                    T\u00a0&gt;\u00a0MIC in most scenarios. In contrast, achieving the more aggressive target of 100% \u0192T\u00a0&gt;\u00a0MIC required a regimen of every 6 h; for MIC\u00a0\u2265\u00a04\u00a0mg\/L pathogens, this needed to be coupled with an extended infusion time of 3 h. Furthermore, continuous infusion regimens demonstrated a distinct advantage in critically ill patients. This study successfully established a population PK model of meropenem and provided a reference for dosing adjustment based on clinical severity and renal function.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.70067","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:40:48Z","timestamp":1780630848000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic\u2010Based Meropenem Dosing in Critically and Non\u2010Critically Ill Patients with Mixed Gram\u2010Negative Bacterial Infections"],"prefix":"10.1002","volume":"15","author":[{"given":"Shuo","family":"Shi","sequence":"first","affiliation":[{"name":"College of Pharmacy Hebei Medical University  Shijiazhuang China"},{"name":"Department of Pharmacy Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy  Shijiazhuang Hebei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Cui","sequence":"additional","affiliation":[{"name":"College of Pharmacy Hebei Medical University  Shijiazhuang China"},{"name":"Department of Pharmacy Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy  Shijiazhuang Hebei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqing","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Pharmacy Hebei Medical University  Shijiazhuang China"},{"name":"Department of Pharmacy Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy  Shijiazhuang Hebei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy  Shijiazhuang Hebei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjun","family":"Bai","sequence":"additional","affiliation":[{"name":"College of Pharmacy Hebei Medical University  Shijiazhuang China"},{"name":"Department of Pharmacy Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy  Shijiazhuang Hebei China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iccn.2022.103227"},{"key":"e_1_2_11_3_1","first-page":"3676","article-title":"Research advances on virulence factors, secretion systems, and metal metabolism in Acinetobacter baumannii","volume":"23","author":"Zhu Z","year":"2025","journal-title":"Chin J Nosocomiol."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2021.107734"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020328"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868060-00006"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13369"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06050-1"},{"issue":"5","key":"e_1_2_11_9_1","article-title":"Beta\u2010lactam dose optimisation in the intensive care unit: targets, therapeutic drug monitoring and toxicity","volume":"12","author":"Legg A","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-020-00504-w"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199528040-00002"},{"key":"e_1_2_11_12_1","unstructured":"Package insert of meropenem.China Medical Information Platform. Accessed on November 2 2025.https:\/\/www.dayi.org.cn\/drug\/1152383.html."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1871-2"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc10441"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9071401"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.01.015"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S489603"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00321-22"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550010-00007"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00845-22"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00822-22"},{"issue":"9","key":"e_1_2_11_23_1","article-title":"Precision dosing of meropenem in adults with normal renal function: insights from a population pharmacokinetic and Monte Carlo simulation study","volume":"13","author":"Kim YK","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01312-22"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2022-003535"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.10.025"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.4235\/agmr.24.0144"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2023.105107"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_11_30_1","unstructured":"MIC and zone diameter distributions.European Committee on Antimicrobial Susceptibility Testing (EUCOST). Accessed on November 19 2025.https:\/\/mic.eucast.org\/search\/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=\u20101&search%5Bspecies%5D=411&search%5Bdisk_content%5D=\u20101&search%5Blimit%5D=50"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx209"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G467"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv288"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201667"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0018578718779009"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/61.16.1682"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq044"},{"issue":"3","key":"e_1_2_11_38_1","first-page":"283","article-title":"Stability of generic brands of meropenem reconstituted in isotonic saline","volume":"81","author":"Carlier M","year":"2015","journal-title":"Minerva Anestesiol"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.006"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5004-296"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy790"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.70067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:55:21Z","timestamp":1783331721000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.70067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/cpdd.70067"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.70067","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70067"}}